Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient

David P Lustenberger1, Jaymes D Granata, Thomas J Scharschmidt

  • 1Department of Orthopaedics, The Ohio State University, Columbus, Ohio, USA.

Orthopedics
|November 5, 2011
PubMed

Insights

Voriconazole, an antifungal medication, can cause periostitis deformans, a bone condition. Discontinuing voriconazole resolved the patient's symptoms, highlighting a simple cure for this rare side effect.

Area of Science:

  • Medical Case Study
  • Pharmacology
  • Orthopedics

Background:

  • Voriconazole is a potent antifungal medication approved for invasive fungal infections, particularly in immunocompromised patients.
  • Long-term voriconazole use can lead to rare side effects, potentially unfamiliar to orthopedic surgeons.
  • Early recognition of voriconazole-associated periostitis can prevent extensive diagnostic workups.

Observation:

  • A lung transplant patient on long-term voriconazole presented with multifocal periostitis in hand phalanges.
  • Radiographs revealed significant periosteal involvement consistent with periostitis deformans.
  • The patient exhibited normal joint mobility and gait despite bone abnormalities.

Findings:

  • Voriconazole was identified as the likely cause of periostitis deformans.
  • Switching to itraconazole led to the resolution of the patient's symptoms.
  • This case highlights a benign, reversible condition linked to voriconazole therapy.

Implications:

  • Orthopedic surgeons should consider voriconazole-associated periostitis in patients with unexplained bone pain and radiographic findings.
  • Prompt diagnosis and discontinuation of voriconazole can lead to symptom resolution.
  • Understanding this adverse effect can streamline patient management and avoid unnecessary investigations.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...